The Technical Analyst
Silverback Therapeutics, [SBTX]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Silverback Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.03% $5.87
/ 9 nov 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 550.43 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 93.77 mill |
| Avg Daily Volume: | 0.171 mill |
| RATING 2022-11-10 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 5.54 - 6.20 ( +/- 5.64%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-05-17 | Lowenthal Richard E | Sell | 1 050 000 | Common Stock |
| 2023-05-17 | Lowenthal Richard E | Sell | 1 050 000 | Common Stock |
| 2023-05-17 | Lowenthal Richard E | Buy | 1 050 000 | Common Stock |
| 2023-05-17 | Lowenthal Richard E | Buy | 1 050 000 | Common Stock |
| 2024-01-02 | Lowenthal Richard E | Buy | 880 000 | Stock option (right to buy) |
| INSIDER POWER |
|---|
| 72.49 |
| Last 97 transactions |
| Buy: 39 434 245 | Sell: 5 326 539 |
Forecast:
01:40 - $5.87
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.87 (1.03% ) |
| Volume | 0.117 mill |
| Avg. Vol. | 0.171 mill |
| % of Avg. Vol | 68.07 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SBTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SBTX
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Latest Press Releases
2022-08-22 09:38:00 - Press Release
Shareholder Investigation Notice: Halper Sadeh Llp Investigates Hngr, Sbtx, Iea, Zy
New york , aug. 22, 2022 /prnewswire/ -- halper sadeh llp, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: hanger, inc. (nyse: hngr)'s sale to patient square capital for $18.75 in cash per share. if you are a hanger shareholder, click here to learn more about your rights and options.
2022-08-15 09:00:00 - Press Release
Shareholder Investigation Notice: Halper Sadeh Llp Investigates Sbtx, Iea, Pbfx, Rmo
New york , aug. 15, 2022 /prnewswire/ -- halper sadeh llp, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: silverback therapeutics, inc. (nasdaq: sbtx) 's merger with ars pharmaceuticals, inc. under the terms of the merger agreement, assuming that silverback's net cash at closing is $240 million, silverback equity holders are expected to own approximately 37% of the combined company. if you are a silverback shareholder, click here to learn more about your rights and options.
2022-03-31 16:00:00 - Press Release
Silverback Therapeutics Updates Strategic Priorities And Reports Fourth Quarter And Full Year 2021 Financial Results
Seattle--(business wire)--silverback therapeutics, inc. (nasdaq: sbtx) (“silverback”), a biopharmaceutical company leveraging its proprietary immunotac technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today provided an update on strategic priorities and reported financial results for the fourth quarter and full year ended december 31, 2021. “upon comprehensive review of our clinical and preclinical data for our tlr8 oncology programs, we have made the decision to discontinue the development of sbt6050 and sbt6290, and focus our resources on sbt8230 for chronic hbv as well as our immunotac discovery programs,” said laura shawver, ph...
2021-11-09 06:00:00 - Press Release
Class Action Update For Fb, Ontf And Sbtx: Levi & Korsinsky, Llp Reminds Investors Of Class Actions On Behalf Of Shareholders
New york, ny / accesswire / november 9, 2021 / levi & korsinsky, llp announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
2021-10-01 16:07:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Silverback Therapeutics, Inc. - Sbtx
New york, new york--(newsfile corp. - october 1, 2021) - pomerantz llp is investigating claims on behalf of investors of silverback therapeutics, inc. ("silverback" or the "company") (nasdaq: sbtx). such investors are advised to contact robert s. willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.the investigation concerns whether silverback and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [click here for information about...
Latest News
2022-07-28 20:22:35 - PennyStocks
Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins
Penny stocks to watch right now The post Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-01 11:20:02 - Benzinga
Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce
Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays off more than a quarter of its staff. Silverback will continue the advancement of early-stage discovery research.
2022-03-31 19:11:18 - GeekWire
Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce
Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report.
2022-02-19 06:15:16 - 24/7 Wall Street
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
2021-10-01 16:07:00 - Newsfile Corp
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Silverback and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...
2021-09-21 17:56:00 - Newsfile Corp
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Silverback and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information...
2021-09-19 23:23:00 - PRNewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
NEW YORK, Sept. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX).
2021-09-16 07:45:15 - Benzinga
Silverback Therapeutics Presents Initial Safety Data From Solid Tumor Combo Therapy Trial
Silverback Therapeutics Inc (NASDAQ: SBTX) has presented interim data from a Phase 1/1b study of SBT6050 as a monotherapy and in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab). Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21).
2021-09-16 03:30:00 - Business Wire
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced
2021-09-14 20:03:00 - PRNewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
NEW YORK, Sept. 14, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX).